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A Preliminary Evaluation of Azathioprine (Imuran®)
in the Treatment of Multiple Sclerosis
W i l l i a m G. Tucker, M . D . *
K. H . Kapphahn, M.D.**

A theoretical approach to the unknown etiology of multiple sclerosis is presented
in this preliminary study which reports the results of empiric treatment
with
azathioprine. Imuran® therapy produced stabilization of the disease, neurological
improvement, and no progress of neurological dysfunction or loss of any regained
function. Evidence points toward a viral-induced immunological defect.
Abnormal
gamma globulins found in the cerebral spinal fluid suggest an immunological
etiology.

tiple sclerosis.-' " The clinical course,
the pathological pattern of the acute
foci, and the finding of abnormal gamma globulins relate as being similar to
the rejection phenomenon of renal
homotransplants.*'With this immunological implication of etiology, six patients with firm diagnoses of multiple
sclerosis have been treated with Imuran® .
Methods and Procedures
Patients in this study have had a
condition diagnosed as multiple sclerosis for a minimum of three years, with
repetitive and progressive exacerbations documented for more than two
years. In all patients, a trial of corticotrophin therapy failed to prevent progression of the disease process.
Pretreatment laboratory tests were
required to be within normal limits,
i.e., alkaline phosphatase < 4 Bodansky units, white blood count 4,000-

Multiple sclerosis is characterized by
acute exacerbations of neurological
dysfunction with intercurrent periods of
improvement and quiescence. The lesions underlying this sequence of events
are multi-focal plaques of demyelination, disseminated irregularly throughout the cerebral spinal axis, and occur
in successive crops over a period of
years. Demyelination begins at the
peripheral myelin sheath, and spreads
inwardly toward the axis cylinder, suggesting an external etiological cause.
Some lymphocytic perivascular infiltration, with acute myelin edema, is found
in fresh lesions.^ A secondary gliosis
develops in older foci.
There is evidence that abnormal
gamma globulins are found in the cerebral spinal fluid of patients with mul*Division of Oncology
**Division of Neurology
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10,000/cu mm, hemoglobin >11.0
gm/100 cc, and platelet count
> 150,000/cu mm. Serum protein electrophoresis also required normal values. Progress laboratory tests of WBC,
hemoglobin, and platelet counts were
made weekly for the first eight weeks;
and monthly thereafter.
Cerebral spinal fluid (CSF), serum
immunoglobulins, and viral antibody
titers were determined pretreatment
and at various times during treatment.
These results will be discussed in a
later paper, when statistical significance
is established.
Patients were treated in the Oncology Division but were evaluated in the
Neurology Department.
Results
No toxic effects were noted either
clinically or by progress laboratory
studies when Imuran was administered
at a dosage of 50 mg twice a day.
Initial improvement was noted at
four weeks, and maximum return of
function was documented by the eighth
week of therapy. In some cases, motor
function improved in excess of the
"Slight" neurological improvement
noted in the chart below. However,

Patient

Age

Sex

B.T.
V.S.
J.T.
M.B.
*E.B.
EW.

29
24
38
41
38
42

F
M
M
F
M
M

this was felt to be only minimal neurological improvement. Due to the stability of the disease for a prolonged
period, the patients were able to improve active functions of muscle groups
through physiotherapy.
Discussion
"It is axiomatic that no immunological reaction takes place against the
normal constituents of the body. No
other situation is tolerable in health,
and the multitude of serious diseases
which develop when transgression of
this rule takes place merely underlines
its importance." ®
Evidence points toward such a transgression of the self-recognition system
in patients with multiple sclerosis. Theoretically, the immunological mechanism is complete at birth. Early evidence
of an increased infectious disease viral
titer in the CSF that is not abnormal in
the serum' would seem to imply that a
defect, infectious-disease-induced, alters the lymphocyte-recognition of the
nervous system, which is now foreign
to self. The delayed sensitivity then occurring results in production of antibodies and subsequently leads to rejection. This could account for the ab-

Imuran Dosage Months
mg/kg/day
Treated
2.2
1.8
1.8
1.4
1.8
1.6

18
15
13
13
6
6

Neurological Improvement
Visual-^-^-^ Vibratory-fHVisual-f
Motor-lMotor-IVisual-h-h
Motor-fVisual-f
Motor-f
Visual-IMotor+
VisuaH-F

Legend:
* Lost to follow-up after six months.
-|- Slight improvement.
-|--|- Moderate improvement.
-|--|--|- Marked improvement.

Imuran in Multiple Sclerosis
In this preliminary report of treatfnent of multiple sclerosis with Imuran, an immunological etiology is suggested. The term autoimmune is not
applicable. Abnormal gamma globulins and infectious disease viral titers
found in the CSF suggest a viral-induced immunological defect.
Attempts are being made to determine the associated globulin component and the effect of Imuran on this
immunoglobulin. This work will be
reported at a later date.

normal globulin in the CSF and the
pathological picture of early lesions
with perivascular infiltration of lymphocytes and associated edema.
The retrospective history of multiple
sclerosis, prior to diagnosis, varies and
covers a span of several years. It is conceivable that exacerbation of neurological dysfunction exists for several
years prior to recognition, thus accounting for the time delay between
the viral infectious disease and documented onset of multiple sclerosis.
Prior to Imuran therapy, cyclic exacerbations and progressive neurological deterioration were documented. In
agreement with Miller's findings, all
patients were treated with corticosteroids and demonstrated continued progress of their disease.*
The six patients with a diagnosis of
multiple sclerosis for at least three
years, and a minimum of two years of
prior cyclic acute exacerbations of neurological dysfunction, were successfully
treated from 6 to 18 months with doses
of 1.4-2.2 mg/kg/day of Imuran. The
effects of Imuran therapy included stabilization of the disease, neurological
improvement, no progression of neurological dysfunction or loss of any
regained function. Clinically, it was not
anticipated to regain neurological
function but to achieve a stabilization
of the disease. The neurological improvement is accounted for on the basis of reduction of edema. The most
marked improvement has been in those
patients with the most rapidly progressive disease and severe visual defects. No detectable improvement of
ataxia has been recorded. The dosage
schedule of Imuran used in this program is relatively safe and there is
good patient tolerance.

Summary
This preliminary study presents a
theoretical approach to the unknown
etiology of multiple sclerosis, and reports the results of empiric treatment
with azathioprine (Imuran®). Six patients have been treated. Abnormal
gamma globulins found in the cerebral
spinal fluid suggest an immunological
etiology. The term autoimmune is not
applicable; evidence points toward a
viral-induced immunological defect.
Imuran therapy produced stabilization
of the disease and neurological improvement, with no progression of neurological dysfunction or loss of any regained function.
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